{"id":11190,"date":"2026-11-06T02:32:44","date_gmt":"2026-11-06T07:32:44","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11190"},"modified":"2026-11-06T02:32:45","modified_gmt":"2026-11-06T07:32:45","slug":"medicure-will-be-largest-gainer-of-2027","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/medicure-will-be-largest-gainer-of-2027\/","title":{"rendered":"Medicure Will Be #1 Largest Gainer of 2027"},"content":{"rendered":"\n
\n

Medicure (TSXV: MPH)<\/strong> or MCUJF<\/strong> on the U.S. OTC was originally founded<\/strong><\/span> in September 1997 as a biotechnology company<\/strong> focused primarily<\/strong><\/span> on developing treatments<\/strong><\/span> for cardiovascular diseases<\/strong><\/span>. In November 1999, the company went public<\/strong><\/span> on the Alberta Stock Exchange<\/strong> for the purpose of developing<\/span> MC-1<\/strong>, a drug that Medicure <\/strong>currently has in Phase 3 trials<\/strong>, yet absolutely nobody<\/strong><\/span> knows the trials are even taking place. After we are done accumulating<\/strong><\/span> our initial<\/span> positions<\/strong> if we all make just a small effort<\/strong><\/span> to inform<\/span> biotech investors<\/strong> about the company on social media, it will rapidly rise<\/strong><\/span> to $15-$20 per share<\/strong> within weeks because no<\/span> other biotech stock<\/strong> in Phase 3 clinical trials<\/strong> has a market cap<\/strong> this low<\/strong><\/span>, period. Medicure’s FDA approval<\/span> odds<\/strong> are among the highest<\/strong><\/span> of any publicly traded<\/strong><\/span> biotech company<\/strong> with active<\/span> Phase 3 clinical trials<\/strong>.<\/p>\n\n

Dr. Phillip Pearl<\/strong> the lead<\/span> investigator<\/strong> for Medicure’s MEND-PNPO Phase 3 trial<\/strong> evaluating<\/span> MC-1 <\/strong>is the William G. Lennox Chair and Professor of Neurology<\/strong> at Harvard Medical School <\/strong>the world’s #1 ranked<\/span> medical school<\/strong>. He is a world-renowned expert<\/strong><\/span> in pediatric neurology<\/strong>, clinical neurophysiology<\/strong>, and childhood epilepsy<\/strong>… and widely considered the world’s #1 top expert<\/strong><\/span> on rare inherited metabolic disorders<\/strong><\/span> that cause seizures<\/strong><\/span> and neurological issues<\/strong><\/span> in infants<\/strong> and children<\/strong>. He serves as the Director of Epilepsy and Clinical Neurophysiology<\/strong> at Boston Children’s Hospital<\/strong>, which is the primary<\/span> pediatric teaching hospital affiliated<\/span><\/strong> with Harvard Medical School<\/strong>.<\/p>\n\n

Medicure<\/strong> began developing<\/span> MC-1<\/strong> in 1997, based on pioneering<\/span> cardiovascular research conducted<\/span><\/strong> by Dr. Naranjan Dhalla<\/strong> at the University of Manitoba<\/strong>, with the goal<\/strong><\/span> of protecting<\/strong><\/span> the heart<\/strong><\/span> from damage<\/strong><\/span> caused by heart attacks<\/strong><\/span> and cardiac surgery<\/strong>. <\/font>In February 2000, Medicure <\/strong>was preparing<\/strong><\/span> for the launch<\/strong><\/span> of Phase 1 trials<\/strong>, and the stock hit a high<\/strong><\/span> of $84 per share<\/strong> with a market cap<\/strong> of CAD$212 million<\/strong><\/span>.<\/p>\n\n

In April 2001, Medicure successfully completed<\/span> Phase 1 clinical trials<\/strong> of MC-1<\/strong>, and by March 2002, the company had graduated<\/strong><\/span> to the Toronto Stock Exchange<\/strong> while simultaneously advancing<\/span> MC-1<\/strong> into Phase 2 clinical trials<\/strong>. In February 2004, after positive<\/span> Phase 2 clinical results<\/strong> for MC-1<\/strong>, followed by FDA authorization<\/span><\/strong> for a much larger<\/span> clinical trial<\/strong> and a major<\/span> U.S. listing<\/strong> on the American Stock Exchange<\/strong>, Medicure<\/strong> was trading on the Toronto Stock Exchange for $42.75 per share<\/strong> with a market cap<\/strong> of CAD$188.44 million<\/strong><\/span>.<\/p>\n\n

Medicure’s 2001-2003 Phase 2 trial<\/strong> involved 60 patients undergoing angioplasty. The larger<\/span> 2004-2005 Phase 2 trial<\/strong> involved 902 heart bypass surgery patients and had successful results<\/strong><\/span> in December 2005. In November 2006, Medicure<\/strong> began enrolling<\/span> 3,000 patients<\/strong> in its Phase 3 MEND-CABG II trial<\/strong> that evaluated whether the cardioprotective drug MC-1<\/strong> could reduce major cardiovascular complications<\/strong><\/span> following bypass surgery. In July 2007, MPH<\/strong> was trading on the Toronto Stock Exchange for $22.65 per share<\/strong> with a market cap of CAD$176.22 million<\/strong><\/span>.<\/p>\n\n

From September 1997 through May 2008, Medicure<\/strong> spent<\/strong><\/span> a total of CAD$88.6 million<\/strong> on MC-1 research & development <\/strong>and consistently diluted<\/span> shareholders<\/strong> much like 99% of all other biotech companies. In 2008, Medicure’s Phase 3 trial failed<\/span><\/strong> to meet its primary efficacy endpoint, demonstrating no benefit<\/strong><\/span> of MC-1<\/strong> over a placebo in reducing death<\/strong><\/span> or heart attacks<\/strong><\/span> after surgery.<\/p>\n\n

Medicure stock crashed<\/span><\/strong> in 2008 after the Phase 3 trial<\/strong> for MC-1<\/strong> was a complete and total disaster<\/strong><\/span>… but the company survived<\/strong><\/span> this setback<\/strong><\/span> because in 2006 they had made a smart<\/span> investment<\/strong> by acquiring the rights<\/strong><\/span> to AGGRASTAT<\/strong> for US$19 million<\/strong> an FDA approved cardiovascular drug<\/strong> originally developed<\/strong><\/span> by Merck<\/strong>.<\/p>\n\n

Medicure<\/strong> continues to sell AGGRASTAT<\/strong> today, but its patent expired<\/span><\/strong> in May 2023. In 2025, Medicure generated<\/span> CAD$5.7 million in revenue<\/strong> from AGGRASTAT<\/strong>. When AGGRASTAT revenue<\/strong> began to decline<\/strong><\/span> in 2019, MPH acquired<\/span><\/strong> the rights to ZYPITAMAG<\/strong> for US$7 million<\/strong> a patented<\/span> drug<\/strong> that has seen rapid growth<\/strong><\/span> in recent years. In 2025, Medicure generated<\/span> CAD$6.5 million in revenue<\/strong> from ZYPITAMAG<\/strong>.<\/p>\n\n

The current Phase 3 trial<\/strong> for MC-1<\/strong> is for PNPO deficiency<\/strong> a rare disease<\/strong><\/span> and is fully enrolled<\/strong><\/span> with only 10 patients<\/strong>. This is not a speculative unproven<\/span> 3,000 patient Phase 3 trial <\/strong>like two decades ago. MC-1<\/strong> is pyridoxal-5′-phosphate (PLP)<\/strong> the active form<\/strong><\/span> of vitamin B6<\/strong> and is already proven<\/strong><\/span> to stop seizures<\/strong><\/span> in babies. The trial is going smoothly and multiple patients<\/strong> have already completed<\/strong><\/span> the trial. The final results<\/strong> will be released<\/strong><\/span> in September 2027 with FDA approval<\/strong> likely to occur in the following months, which will result in Medicure receiving<\/span><\/strong> a Priority Review Voucher<\/strong> that it will resell<\/strong><\/span> for US$200 million<\/strong><\/span> in cash<\/strong>. Therefore, over the next ten months, Medicure shares<\/strong> are likely to be revalued from a market cap<\/strong> of US$27.71 million<\/strong> today to a new all-time high<\/span> market cap<\/strong> of US$200 million<\/strong> plus.<\/p>\n\n

We should be charging people thousands of dollars to even be informing them about Medicure. We had no intention of telling anybody about the company and originally planned to buy up all of the shares for ourselves.<\/strong><\/p>\n\n

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This message is meant for informational and educational purposes only.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Medicure (TSXV: MPH) or MCUJF on the U.S. OTC was originally founded in September 1997 as a biotechnology company focused primarily on developing treatments for cardiovascular diseases. In November 1999, the company went public on the Alberta Stock Exchange for the purpose of developing MC-1, a drug that Medicure currently has in Phase 3 trials, yet […]<\/p>\n","protected":false},"author":1,"featured_media":11191,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,414],"class_list":["post-11190","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-mph"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11190"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11190\/revisions"}],"predecessor-version":[{"id":11192,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11190\/revisions\/11192"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11191"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}